Share on

Europe Chlamydia Infection Diagnostics and Therapeutics Market Research Report – Segmented By Product Type, End User and Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) – Industry Size, Share, Trends and Growth Forecast (2023 to 2028)

Published: March, 2023
ID: 4961
Pages: 145
Formats: report pdf report excel report power bi report ppt

The size of the Europe Chlamydia Infection Diagnostics and Therapeutics market was around USD 0.59 billion in 2023. It is expected to grow at a CAGR of 5.9% to reach USD 0.79 billion by 2028. It captures 25% of the global market.

The chlamydia infection diagnostics and therapeutics market have a lot of promise, especially in developing regions such as Europe, due to the growing patient pool and vast unexplored opportunities.

The European market is likely to rise steadily in the foreseeable future, owing to an increased focus on treating sexually transmitted infections across Europe. In addition, improved diagnostic approaches for pelvic inflammatory illness and chlamydial infection symptoms are required in women at high risk of tubal damage. As a result, the number of chlamydia infection diagnoses continues to rise, and key factors such as a large pool of potential patients, government initiatives aimed at improving health care access, improving infrastructure, and increasing healthcare spending are expected to drive the market in Europe.

The number of sexually transmitted illnesses and chlamydia cases rises in Europe, the market for chlamydia infection diagnostics and therapeutics is growing. Furthermore, increasing government initiatives to raise public awareness about STDs and enhance public knowledge about STDs are propelling the market ahead. In particular, in response to the growing economic burden of STDs, government efforts to raise STD awareness have increased. The growth of the chlamydia infection treatment market is fueled by increased government-sponsored efforts to disseminate awareness and measures such as free diagnostic camps to promote regular health check-ups. As a result, the demand for frequent health examinations has risen, as has public awareness of the importance of disease screening.

However, despite the importance of frequent STD testing, many people avoid it owing to social shame; this can lead to poorer screening, prevention, and care, stifling the growth of the chlamydia infection treatment market in the European region. In addition, patients routinely withhold details about their sexual lives from doctors, reducing the market for chlamydia infection therapy. The market's expansion is likely to be constrained by a lack of laboratory experience and knowledge, as well as a lack of healthcare infrastructure. In countries, awareness of chlamydia infection diagnostic tests is extremely low.

This research report on the European chlamydia infection diagnostics and therapeutics market has been segmented & sub-segmented into the following categories:

By Product: 

  • Diagnostics
    • Nucleic Acid Amplification Tests (NAATs)
    • Direct Fluorescent Tests
    • PCR
  • Therapeutics
    • Macrolides
    • Quinolones
    • Sulfonamides
    • Tetracycline
    • Aminopenicillins

By End User: 

  • Diagnostics
    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
  • Therapeutics
    • Hospital Pharmacies
    • Drugstores
    • Retail Pharmacies
    • Online Pharmacies

By Country: 

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, Europe was the second-largest market in 2020. The UK was the market leader in Europe. The region's success has contributed to a well-established healthcare market, rising chlamydia infection rates, and the availability of well-defined reimbursement policies from state and private health insurance firms.

In Europe, countries such as Germany and the United Kingdom are flourishing due to their enormous ability to quickly adopt breakthrough treatments and the presence of several strengthening economies.

KEY MARKET PLAYERS:

Bio-Rad Laboratories, Novartis AG, F Hoffmann-La Roche, Abbott Laboratories, Danaher. Other players in the market include bioMerieux, DiaSorin SpA, Siemens AG, Thermo Fisher Scientific, and Becton Dickinson and Company, a few of the prominent companies in the European market.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample